{
    "Trade/Device Name(s)": [
        "VITEK 2 AST-Gram Negative Levofloxacin",
        "VITEK 2 AST-GN Levofloxacin"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K222378",
    "Predicate Device Reference 510(k) Number(s)": [
        "K072038"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON",
        "LTT",
        "LTW"
    ],
    "Summary Letter Date": "August 4, 2022",
    "Summary Letter Received Date": "August 5, 2022",
    "Submission Date": "August 4, 2022",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Levofloxacin"
    ],
    "Specimen Type(s)": [
        "Aerobic Gram-negative bacilli (isolates)",
        "Bacterial cultures"
    ],
    "Specimen Container(s)": [
        "Saline suspension"
    ],
    "Instrument(s)/Platform(s)": [
        "VITEK 2",
        "VITEK 2 Compact"
    ],
    "Method(s)/Technology(ies)": [
        "Automated microdilution antimicrobial susceptibility testing",
        "Quantitative MIC determination"
    ],
    "Methodologies": [
        "Microdilution",
        "Automated susceptibility testing"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Test Card",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for VITEK 2 AST-Gram Negative Levofloxacin antimicrobial susceptibility test for Gram-negative bacilli using automated microdilution methodology",
    "Indications for Use Summary": "Laboratory aid for determining in vitro susceptibility of Gram-negative bacilli to levofloxacin using VITEK 2 systems, with results reported for specific clinically significant organisms",
    "fda_folder": "Microbiology"
}